Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
Launched by EISAI CO., LTD. · Jun 11, 2014
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Patients diagnosed with Alzheimer's Disease who are to be administered both donepezil hydrochloride and memantine hydrochloride in clinical practice.
- Exclusion criteria:
- • Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.
About Eisai Co., Ltd.
Eisai Co., Ltd. is a global pharmaceutical company headquartered in Japan, dedicated to the research, development, and commercialization of innovative therapeutics that address unmet medical needs. With a strong focus on neurology and oncology, Eisai leverages its extensive expertise in drug discovery and development to advance treatments that improve patient outcomes. Committed to the principles of transparency and collaboration, Eisai actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring that its research aligns with the highest ethical standards. Through its patient-centric approach, Eisai strives to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials